SAN Sanofi

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

 

François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Paris, February 1, 2024. François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024. He will be based in Paris and will succeed Jean-Baptiste Chasseloup de Chatillon who will step down from his role to become Head of Apprentis d’Auteuil. Apprentis d’Auteuil is a foundation that supports adolescents who are struggling in life by providing education, training and integration programs, in France and internationally. Being active in charity work for many years, Jean-Baptise decided to devote the next stage of his career to giving back to society.

François-Xavier will join from Nestle, where he has been the CFO for more than 8 years, providing strong financial leadership and driving sustainable value creation. He is a seasoned executive who has lived and worked in Europe, the U.S, Asia, Africa and Latin America. Before Nestlé, François-Xavier  was the CFO of Takeda Pharmaceuticals, based in Japan, from 2013 to 2015. François-Xavier started his career in pharma, spending the first 14 years at Roussel, Hoechst and Aventis, in various countries. From 2000 to 2008, François-Xavier was the CFO for Danone Asia, after which he was Head of Finance, Treasury and Tax for the Danone Group. Between 2008 to 2013, he was CFO of Millicom, a NASDAQ listed, global mobile phone operator.

Paul Hudson

Chief Executive Officer, Sanofi

“As we enter the next phase of launch and growth, it’s a pleasure to welcome onboard François-Xavier Roger, a CFO with a proven track record in accelerated value creation. Since joining in 2018, Jean-Baptiste de Chatillon has been instrumental in progressing our Play to Win Strategy. Under his leadership, our finance organization has been modernized into a team that supports our mission and execution of our strategy on a daily basis. We are proud of Jean-Baptiste’s next step.”

Jean-Baptise Chasseloup de Chatillon

“Over these last 5 years, I have been privileged to witness the incredible transformation of Sanofi into a company with a strong long-term growth potential. My decision to head Apprentis d’Auteuil was also fuelled by my growing passion for the impact Sanofi has around the world. I thank Paul and all my colleagues at Sanofi for their trust over the years and will be applauding them as they continue to drive forward our strategy.”

François-Xavier Roger

“It is with great enthusiasm that I join Sanofi in this dynamic moment marked by significant transformation. I am excited by the opportunity to further improve patient outcomes and deliver increased shareholder value in the years to come.”

 

Picture of François-Xavier Roger is attached to this email.





 

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul |  25 | 

Nicolas Obrist |  55 | 

Victor Rouault |  40 | 

Investor Relations

Eva Schaefer-Jansen |  39 | 

Arnaud Delépine |  93 |

Corentine Driancourt |  21 |

Felix Lauscher | + 1 908 612 7239 |

Tarik Elgoutni| 7 |

Nathalie Pham |  17 |

Attachments



EN
01/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi reaches agreement with the US government to lowe...

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a framework for lower prices for patients in the US and a tariff-free accord for SanofiShowcases commitment to US manufacturing, innovation, and economic growth Paris, December 19, 2025. Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients ha...

 PRESS RELEASE

Communiqué de presse : Sanofi conclut un accord avec le gouvernement a...

Communiqué de presse : Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation L’accord répond aux quatre demandes du président Trump, établit un cadre pour que les patients américains bénéficient de prix plus bas et exempte Sanofi de droits de douaneL’accord illustre l’engagement de Sanofi à soutenir la production, l’innovation et la croissance économique aux États-Unis Paris, le 19 décembre 2025. Sanofi a an...

 PRESS RELEASE

Press release: Availability of the Q4 2025 Aide memoire

Press release: Availability of the Q4 2025 Aide memoire Availability of the Q4 2025 Aide memoire Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's fourth quarter & full year 2025 results will be published on January 29, 2026. About Sanof...

 PRESS RELEASE

Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire...

Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Mise en ligne du document «Q4 2025 Aide mémoire » Paris, France, le 17 décembre 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q4 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du quatrième tri...

 PRESS RELEASE

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in t...

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseasesEfdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary and key secondary endpoints in phase 2 head-to-head study versus a plasma-derived standard of care Paris, December 17, 2025. The European Medicines Agency...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch